Home
/ MIMS
/ Competitors

MIMS Competitors and Similar CompaniesClear all

MIMS's competitors and similar companies include MD Anderson Cancer Center, Eisai, Shield Therapeutics and Eurofarma.

	MIMS MIMS is a medical company.	MD Anderson Cancer Center MD Anderson Cancer Center is a cancer treatment center.	Eisai Eisai (エーザイ株式会社) is a research-based human healthcare company that discovers, develops, packages, and markets pharmaceutical products.	Shield Therapeutics Shield Therapeutics is a pharmaceutical company developing and commercializing late-stage, mineral-derived pharmaceuticals.	Eurofarma Eurofarma is a pharmaceutical company.
Founding Date	Founding Date 1963	Founding Date 1944	Founding Date 1941	Founding Date 2008	Founding Date 1972
Type	Type Private	Type Subsidiary	Type Public	Type Private	Type Private
Tags	Tags Healthcare drug development hospitals	Tags Healthcare drug development higher education hospitals oncology	Tags Healthcare drug development hospitals oncology pharma	Tags Healthcare drug development hospitals pharma	Tags Healthcare drug development hospitals pharma
Locations	Locations Singapore, SG HQ	Locations Houston, US HQ Conroe, US Houston, US Houston, US Houston, US League City, US Sugar Land, US	Locations Tokyo, JP HQ Melbourne, AU Wien, AT Leuven, BE Mississauga, CA see more	Locations Gateshead, GB HQ Berlin, DE Wollerau, CH London, GB Wilmington, US	Locations BR HQ La Tablada, AR Maipú, CL Bogotá, CO Breña, PE
Employees	Employees 1,263	Employees 22,1641% increase	Employees 11,067	Employees 701% increase	Employees 8,787
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $6b (FY, 2022)	Revenue (est.) ¥789.4b (FY, 2025)	Revenue (est.) £11.9m (FY, 2018)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods ¥128.9b (FY, 2025)	Cost of goods £311k (FY, 2018)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit ¥677.7b (FY, 2025)	Gross profit £11.6m (FY, 2018)	Gross profit N/A
Net income	Net income N/A	Net income ($297.5m) (FY, 2022)	Net income ¥48.1b (FY, 2025)	Net income (£1.8m) (FY, 2018)	Net income N/A